988 completed, 190 unknown, 175 recruiting, 94 terminated. 761 Not applicable, 213 Phase 4, 166 Phase 2, 141 Phase 3, 93 Phase 1.
Follow Psychotic Disorders: new trials by email Literature Review of Psychotic Disorders trials Research Report on Psychotic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis Cannabidiol (CBD), Placebo - Schizophrenia Spectrum Disorders, Cannabis Use | Phase 2 | Withdrawn | University of Maryland, Baltimore | 2050-01-01 | 2021-04-19 | |
| Efficacy of Mindfulness in PREventing Progression to Psychosis in Individuals With an Ultra High Risk for Psychosis MBTP : Mindflulness based training for psychosis - Clinical High Risk for Psychosis (CHR) | Not applicable | Not yet recruiting | Centre Psychothérapique de Nancy | 270 | 2029-04-01 | 2026-03-25 |
| Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 2 Motion Perception Task, Sine Wave Speech Task, Volatility Task - SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder | Not applicable | Not yet recruiting | Washington University School of Medicine | 325 | 2028-04-01 | 2026-10-15 |
| Developing a Virtual Reality-assisted Intervention for Emotion Regulation Difficulties in Psychosis MANOEUVRE therapy - Psychosis, SCHIZOPHRENIA 1 (Disorder) | Not applicable | Not yet recruiting | King's College London | 15 | 2027-09-01 | 2026-06-03 |
| Feasibility and Acceptability of Mobile Mental Health App for SZ and SZA Intervention via mobile application - Schizophrenia, Schizo Affective Disorder | Not applicable | Not yet recruiting | University of Pittsburgh | 44 | 2027-06-01 | 2026-09-16 |
| Feasibility Trial of a Parent Peer-Co-Led Caregiver Group for Pediatric Early Onset Schizophrenia Spectrum Disorders Group Therapy, Treatment as Usual (TAU) - Schizophrenia; Psychosis | Not applicable | Not yet recruiting | Boston Children's Hospital | 20 | 2027-05-01 | 2026-10-09 |
| Testing a Peer-Support Group for Veterans Who Hear Voices Veteran Voices and Visions (VVV), Wellness Recovery Action Planning (WRAP) - Psychotic Disorders, Hallucinations, Auditory | Not applicable | Not yet recruiting | VA Office of Research and Development | 160 | 2027-04-01 | 2026-04-29 |
| NST-SPARK Open-Label Phase 1 STTR (IGNITE) NST-SPARK - Schizophrenia / Schizoaffective Disorder | Not applicable | Not yet recruiting | North Shore Therapeutics, Inc. | 30 | 2027-03-01 | 2026-05-18 |
| Pilot Study of Sensor-Informed Smartphone-based Mental Health Interventions for Mood in Early Psychosis Smartphone-based Mindfulness Exercise, Smartphone-based Psychoeducation, Neutral Control Message - Psychosis, Anxiety | Not applicable | Not yet recruiting | Mclean Hospital | 10 | 2027-01-15 | 2026-10-05 |
| Shared Decision Making for Antipsychotic Medications The Antipsychotic Medication Decision Aid (APM-DA) - Schizophrenia, Schizoaffective Disorder | Not applicable | Not yet recruiting | New York State Psychiatric Institute | 120 | 2027-01-01 | 2026-03-30 |
| Stratification and Treatment in Early Psychosis Study -ASSIST CBD 100 mg/mL Oral Solution, Placeb - Treatment Resistant Psychosis, Psychosis | Phase 3 | Not yet recruiting | University of Oxford | 250 | 2027-01-01 | 2026-10-08 |
| A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia Xanomeline/trospium - Schizophrenia; Psychosis, Cognitive Impairment | Phase 3 | Not yet recruiting | European Group for Research In Schizophrenia | 171 | 2027-01-01 | 2026-05-13 |
| Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia Brexpiprazole, Cariprazine, [11C] PHNO - Schizoaffective Disorder, Schizophreniform Disorder | Phase 1 | Not yet recruiting | New York State Psychiatric Institute | 100 | 2026-12-01 | 2026-07-20 |
| Stratification and Treatment in Early Psychosis Study - PROMOTE Cannabidiol (CBD), Placebo - Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis | Phase 3 | Not yet recruiting | University of Oxford | 586 | 2026-12-01 | 2026-10-08 |
| Online Intervention To Improve Motivation Online Motivation Enhancing Intervention - Schizophrenia Prodromal, SCHIZOPHRENIA 1 (Disorder) | Not applicable | Not yet recruiting | University of Alabama at Birmingham | 60 | 2026-12-01 | 2026-10-13 |
| NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia Perceptual Discrimination Training, Cognitive Control Training - Schizophrenia, Schizoaffective Disorder | Not applicable | Not yet recruiting | University of Minnesota | 168 | 2026-11-02 | 2026-10-02 |
| A Mobile App to Support Mood, Daily Routines and Medication Adherence in Adults With Severe Mental Illness MoodSync, Standard care - Severe Mental Illness, Bipolar Disorder | Not applicable | Not yet recruiting | Alexandria University | 60 | 2026-11-01 | 2026-10-16 |
| Stratification and Treatment in Early Psychosis Study - ENHANCE CBD 100 mg/mL Oral Solution, Placebo - Psychosis, First Episode Psychosis | Phase 3 | Recruiting | University of Oxford | 250 | 2026-10-05 | 2026-10-08 |
| Optimizing CBSST With Executive Function Training for Schizophrenia (R33) E-CBSST, E-SC - Schizophrenia, Schizoaffective Disorder | Not applicable | Not yet recruiting | University of California, San Diego | 106 | 2026-10-01 | 2026-06-23 |
| Dissecting Immunological and Autoimmune Mechanisms of Neuropsychiatric Diseases Neuropsychiatric Symptom | Not yet recruiting | King's College London | 300 | 2026-10-01 | 2026-08-27 |
Showing 20 of 1583. Sign in to see all of them.
Schizophrenia (1054) · Bipolar Disorder (218) · Mental Disorders (134) · Depression (80) · Depressive Disorder, Major (71) · Substance-Related Disorders (49) · Anxiety Disorders (45) · Hallucinations (44) · Mood Disorders (44) · Schizophrenia Spectrum and Other Psychotic Disorders (40) · Marijuana Abuse (30) · Personality Disorders (28) · Psychological Well-Being (28) · Schizophrenia, Paranoid (28)
Schizophrenia Spectrum and Other Psychotic Disorders (1543) · Mental Disorders (1449) · Behavior (281) · Mood Disorders (233) · Pathological Conditions, Signs and Symptoms (220) · Bipolar and Related Disorders (218) · Signs and Symptoms (187) · Nervous System Diseases (166) · Behavioral Symptoms (145) · Neurologic Manifestations (135) · Neurobehavioral Manifestations (110) · Chemically-Induced Disorders (100) · Nutritional and Metabolic Diseases (74) · Depressive Disorder (67) · Neurocognitive Disorders (59)
Risperidone (106) · Therapeutics (67) · Olanzapine (62) · Aripiprazole (59) · Quetiapine Fumarate (47) · Cognitive Behavioral Therapy (38) · ziprasidone (37) · Paliperidone Palmitate (29) · Cognitive Remediation (25) · Transcranial Direct Current Stimulation (22) · Clozapine (17) · Cognitive Training (17) · Exercise (16) · Haloperidol (14) · Transcranial Magnetic Stimulation (14)
VA Office of Research and Development (40) · Yale University (38) · Centre for Addiction and Mental Health (37) · King's College London (25) · New York State Psychiatric Institute (25) · University of Maryland, Baltimore (24) · University of North Carolina, Chapel Hill (24) · Dartmouth-Hitchcock Medical Center (23) · University of California, San Diego (20) · National Institute of Mental Health (NIMH) (19) · University of Minnesota (19) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (18) · Mclean Hospital (18) · Northwell Health (18) · US Department of Veterans Affairs (17)
United States (757) · Canada (147) · United Kingdom (75) · Germany (72) · Spain (64) · France (55) · Israel (44) · Denmark (28) · Australia (27) · China (27) · Taiwan (27) · Hong Kong (26) · Netherlands (26) · Norway (26) · Switzerland (25)
Sophia Vinogradov, MD (14) · Benedicto Crespo-Facorro, Professor (11) · Dror Ben-Zeev, PhD (7) · William Honer, MD (7) · Eric Granholm, PhD (5) · Hsin-An Chang, M.D. (5) · Katherine Beebe, PhD (5) · Mark Weiser, MD (5)
PMID 33539561, PMID 29523415, PMID 20840778, PMID 26934062, PMID 34004383, PMID 38244179, PMID 20537128, PMID 20537130, PMID 20658320, PMID 21334602, PMID 22710617, PMID 22992330, PMID 23522057, PMID 23817024, PMID 24423017, PMID 25273286, PMID 25979608, PMID 26107752, PMID 26160288, PMID 26200928, PMID 26493637, PMID 26494483, PMID 27617637, PMID 28406662, PMID 28433500, PMID 28740827, PMID 29207980, PMID 29856773, PMID 30097769, PMID 30260448, PMID 30704863, PMID 30953588, PMID 31279534, PMID 31307859, PMID 31415936, PMID 31811557, PMID 31902581, PMID 32141724, PMID 32799938, PMID 33861952, PMID 33878489, PMID 33914891, PMID 34662778, PMID 34894307, PMID 35128308, PMID 36173600, PMID 36369028, PMID 36418846, PMID 36711165, PMID 36931706
P50MH119569 (5), 2009 (4), 2018 (4), 2025 (4), N01MH090001 (4), 2019 (3), N01MH90001 (3), R01MH073673 (3), 2005 (2), 2015 (2), 2017 (2), 2023 (2), I01RX000180 (2), K23DA050808 (2), K23MH126312 (2)